ADPT Adaptive Biotechnologies Corp

Price (delayed)

$17.46

Market cap

$2.79B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$2.92B

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 66
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 43

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the ...

Highlights
The gross profit has surged by 88% year-on-year and by 8% since the previous quarter
ADPT's EPS has surged by 65% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of ADPT

ADPT stock price

How has the Adaptive Biotechnologies stock price performed over time
Intraday
9.19%
1 week
14.94%
1 month
20.41%
1 year
74.95%
YTD
7.51%
QTD
25.79%

Financial performance

How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$295.41M
Gross profit
$222.32M
Operating income
-$46.73M
Net income
-$49.68M
Gross margin
75.3%
Net margin
-16.8%
The gross profit has surged by 88% year-on-year and by 8% since the previous quarter
Adaptive Biotechnologies's operating margin has surged by 79% YoY and by 23% QoQ
ADPT's net margin has surged by 78% year-on-year and by 22% since the previous quarter
Adaptive Biotechnologies's operating income has surged by 67% YoY and by 18% QoQ

Price vs fundamentals

How does ADPT's price correlate with its fundamentals

Growth

What is Adaptive Biotechnologies's growth rate over time

Valuation

What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
12.43
P/S
9.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.89
ADPT's EPS has surged by 65% year-on-year and by 15% since the previous quarter
ADPT's P/B is 123% above its 5-year quarterly average of 5.1 and 7% above its last 4 quarters average of 10.6
ADPT's equity is up by 14% year-on-year
The revenue has soared by 56% YoY and by 7% from the previous quarter
ADPT's price to sales (P/S) is 19% lower than its 5-year quarterly average of 10.4

Efficiency

How efficient is Adaptive Biotechnologies business performance
ADPT's return on sales has surged by 81% year-on-year and by 26% since the previous quarter
The ROIC has soared by 67% YoY and by 19% from the previous quarter
The ROE has soared by 63% YoY and by 19% QoQ
Adaptive Biotechnologies's ROA has soared by 62% YoY and by 16% from the previous quarter

Dividends

What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADPT.

Financial health

How did Adaptive Biotechnologies financials performed over time
The total assets is 80% more than the total liabilities
The current ratio has grown by 15% YoY
The quick ratio is up by 14% year-on-year
ADPT's debt is 3.8% smaller than its equity
ADPT's debt to equity is down by 17% year-on-year
ADPT's equity is up by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.